Viridian Therapeutics, Inc.\DE Lessee, Operating Lease, Liability, to be Paid, Year Three in USD from Q4 2022 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Viridian Therapeutics, Inc.\DE quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three history and growth rate from Q4 2022 to Q3 2025.
  • Viridian Therapeutics, Inc.\DE Lessee, Operating Lease, Liability, to be Paid, Year Three for the quarter ending September 30, 2025 was $854K, a 39.3% increase year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Year Three, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Three, YoY Quarterly Growth (%)

Viridian Therapeutics, Inc.\DE Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $854K +$241K +39.3% Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $627K +$143K +29.5% Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $627K +$468K +294% Mar 31, 2025 10-Q 2025-05-06
Q4 2024 $613K +$139K +29.3% Dec 31, 2024 10-K 2025-03-03
Q3 2024 $613K +$139K +29.3% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $484K +$10K +2.11% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $159K -$71K -30.9% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $474K +$229K +93.5% Dec 31, 2023 10-K 2024-02-27
Q3 2023 $474K Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $474K Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $230K Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $245K Dec 31, 2022 10-K 2023-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.